PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?

Estrogen receptor (ER) signaling represents the main driver of tumor growth and survival in luminal breast cancer (BC). Despite the efficacy of endocrine agents, many patients with luminal BC do not respond to endocrine therapy and many others develop endocrine resistance over time, due to the activ...

Full description

Saved in:
Bibliographic Details
Published in:Breast Care (Basel)
Main Authors: Schettini, Francesco, Buono, Giuseppe, Trivedi, Meghana V., De Placido, Sabino, Arpino, Grazia, Giuliano, Mario
Format: Artigo
Language:Inglês
Published: S. Karger GmbH 2017
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5704698/
https://ncbi.nlm.nih.gov/pubmed/29234247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000481657
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items